drugset / Trial / NCT03903133
Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients
NaSingle-groupOpen-labelSupportive care
Summary
This study objectives to assess the role of endothelial monocyte-activating polypeptide II (EMAP II) as a marker of endothelial dysfunction and disturbed angiogenesis in sickle cell disease and to identify its correlation With the oxidative status.
Timeline
- Start
- 2016-06-01
- Primary completion
- 2023-05-01
- Completion
- 2023-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin E | Other / unclassified | 400 mg | Oral |
| Subject | Vitamin E | Other / unclassified | 600 mg | Oral |